查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1335251

真实世界证据解决方案的全球市场

Real World Evidence Solutions
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 246 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球真实证据解决方案市场将达到 39 亿美元

随着COVID-19之后商业环境的变化，现实世界证据解决方案的全球市场规模预计在2022年为13亿美元，到2030年将达到39亿美元，并且从2022年到2030年预计将增长年复合成长率为 14.3%。服务业是本报告分析的细分市场之一，预计复合年增长率为 15.5%，到分析期结束时将达到 26 亿美元。考虑到疫情后持续的复苏，未来八年资料领域的复合年复合成长率已调整为 12.1%。

美国市场预计将增长3.965亿美元，中国年复合成长率为13.3%

预计 2022 年美国现实世界证据解决方案市场价值将达到 3.965 亿美元。作为世界第二大经济体，预计到2030年，中国的市场规模将达到6.526亿美元，2022年至2030年的分析期间年复合成长率为13.3%。其他值得注意的地域市场包括日本和加拿大，预计从 2022 年到 2030 年，这两个市场将分别增长 13% 和 12%。在欧洲，德国的年复合成长率预计约为 10.1%。

受访企业示例

  • Aetion
  • Cognizant Technology Solutions US Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

目录

第1章调查方法

第2章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和促进因素
  • 全球市场预测

第3章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 意大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 世界其他地区

第4章竞争

简介目录
Product Code: MCP14362

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Real World Evidence Solutions Market to Reach $3.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Real World Evidence Solutions estimated at US$1.3 Billion in the year 2022, is projected to reach a revised size of US$3.9 Billion by 2030, growing at aCAGR of 14.3% over the period 2022-2030. Services, one of the segments analyzed in the report, is projected to record 15.5% CAGR and reach US$2.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Data Sets segment is readjusted to a revised 12.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $396.5 Million, While China is Forecast to Grow at 13.3% CAGR

The Real World Evidence Solutions market in the U.S. is estimated at US$396.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$652.6 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13% and 12% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Select Competitors (Total 46 Featured) -

  • Aetion
  • Cognizant Technology Solutions U.S. Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Real World Evidence Solutions - Global Key Competitors Percentage Market Share in 2020 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Data Sets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 13: World Real World Evidence Solutions Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Devices Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for Pharmaceutical & Medical Devices Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 16: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 17: USA 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 18: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: USA 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Canada 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Canada 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • JAPAN
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Japan 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Japan 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • CHINA
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 28: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: China 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 30: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: China 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • EUROPE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 33: Europe 8-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Europe 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Europe 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • FRANCE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: France 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 40: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 41: France 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • GERMANY
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Germany 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • ITALY
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Italy 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Italy 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • UNITED KINGDOM
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: UK 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 52: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 53: UK 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Rest of World 8-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2023 & 2030
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Rest of World 8-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2023 & 2030

IV. COMPETITION